BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Barclays maintains overweight on Lupin
Strong growth in US to continue. Expect outperformance to continue in 2014. Strong focus on branded segment, leveraging Suprax, a drug for bacterial infections. Target Rs 1019.